Arlington Partners LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 287.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,987 shares of the medical instruments supplier's stock after purchasing an additional 13,342 shares during the quarter. Arlington Partners LLC's holdings in Becton, Dickinson and Company were worth $4,120,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Becton, Dickinson and Company by 50.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after purchasing an additional 27,581 shares in the last quarter. Foster Victor Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $6,406,000. Ritholtz Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $224,000. Finally, Assenagon Asset Management S.A. lifted its holdings in Becton, Dickinson and Company by 1.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 8,047 shares of the medical instruments supplier's stock valued at $1,843,000 after purchasing an additional 79 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Insider Buying and Selling at Becton, Dickinson and Company
In related news, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now directly owns 4,887 shares in the company, valued at $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president now owns 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Trading Up 0.5%
Shares of NYSE:BDX traded up $0.86 during mid-day trading on Friday, reaching $170.83. The stock had a trading volume of 3,070,304 shares, compared to its average volume of 2,036,255. The firm has a market cap of $48.96 billion, a PE ratio of 32.60, a price-to-earnings-growth ratio of 1.28 and a beta of 0.25. The firm has a 50 day simple moving average of $176.53 and a two-hundred day simple moving average of $209.51. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. Becton, Dickinson and Company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period last year, the company posted $3.17 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a yield of 2.44%. Becton, Dickinson and Company's payout ratio is 79.39%.
Analysts Set New Price Targets
Several analysts have weighed in on the stock. Piper Sandler cut shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Barclays reduced their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, Morgan Stanley cut their target price on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $219.22.
Read Our Latest Stock Analysis on BDX
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
